{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:44:23Z","timestamp":1788291863631,"version":"build-2803163510"},"reference-count":91,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Despite the tremendous progress that has occurred in recent years in cell biology and oncology,\nin chemical, physical and computer sciences, the disease cancer has continued as the major\ncause of death globally. Research organizations, academic institutions and pharmaceutical companies\ninvest huge amounts of money in the discovery and development of new anticancer drugs. Though\nmuch effort is continuing and whatever available approaches are being attempted, the success of\nbringing one effective drug into the market has been uncertain. To overcome problems associated with\ndrug discovery, several approaches are being attempted. One such approach has been the use of\nknown, approved and marketed drugs to screen these for new indications, which have gained considerable\ninterest. This approach is known in different terms as \u201cdrug repositioning or drug repurposing.\u201d\nDrug repositioning refers to the structure modification of the active molecule by synthesis, in vitro\/\nin vivo screening and in silico computational applications where macromolecular structure-based drug\ndesign (SBDD) is employed. In this perspective, we aimed to focus on the application of repositioning\nor repurposing of essential drug moieties present in drugs that are already used for the treatment of\nsome diseases such as diabetes, human immunodeficiency virus (HIV) infection and inflammation as\nanticancer agents. This review thus covers the available literature where molecular modeling of\ndrugs\/enzyme inhibitors through SBDD is reported for antidiabetics, anti-HIV and inflammatory diseases,\nwhich are structurally modified and screened for anticancer activity using respective cell lines.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557523666230509123036","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:13:17Z","timestamp":1683781997000},"page":"60-91","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anticancer Drug Discovery By Structure-Based Repositioning Approach"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-6858","authenticated-orcid":true,"given":"Dharti H.","family":"Modh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Erandwane, Pune, 411038, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-5401","authenticated-orcid":true,"given":"Vithal M.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University,\nErandwane, Pune, 411038, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"Langedijk J.","year":"2015","unstructured":"Langedijk J.; Mantel-Teeuwisse A.K.; Slijkerman D.S.; Schutjens M.H.D.B.; Drug repositioning and repurposing: Terminology and definitions in literature. Drug Discov Today 2015,20(8),1027-1034","journal-title":"Drug Discov Today"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","volume":"14","author":"Oprea T.I.","year":"2012","unstructured":"Oprea T.I.; Mestres J.; Drug repurposing: Far beyond new targets for old drugs. AAPS J 2012,14(4),759-763","journal-title":"AAPS J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/17460441.2021.1912733","volume":"16","author":"Gil C.","year":"2021","unstructured":"Gil C.; Martinez A.; Is drug repurposing really the future of drug discovery or is new innovation truly the way forward? Expert Opin Drug Discov 2021,16(8),829-831","journal-title":"Expert Opin Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/1386207317666140122101631","volume":"17","author":"Song Y.","year":"2014","unstructured":"Song Y.; Chen W.; Kang D.; Zhang Q.; Zhan P.; Liu X.; \u201cOld friends in new guise\u201d: Exploiting privileged structures for scaffold re-evolution\/refining. Comb Chem High Throughput Screen 2014,17(6),536-553","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.csbj.2020.04.004","volume":"18","author":"Parisi D.","year":"2020","unstructured":"Parisi D.; Adasme M.F.; Sveshnikova A.; Bolz S.N.; Moreau Y.; Schroeder M.; Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs. Comput Struct Biotechnol J 2020,18,1043-1055","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fphar.2017.00298","volume":"8","author":"March-Vila E.","year":"2017","unstructured":"March-Vila E.; Pinzi L.; Sturm N.; Tinivella A.; Engkvist O.; Chen H.; Rastelli G.; On the integration of in silico drug design methods for drug repurposing. Front Pharmacol 2017,8,298","journal-title":"Front Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"112851","DOI":"10.1016\/j.ejmech.2020.112851","volume":"207","author":"Modi S.J.","year":"2020","unstructured":"Modi S.J.; Kulkarni V.M.; Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-\u03b2 induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med Chem 2020,207,112851","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","volume":"16","author":"Tanoli Z.","year":"2021","unstructured":"Tanoli Z.; V\u00e4h\u00e4-Koskela M.; Aittokallio T.; Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov 2021,16(9),977-989","journal-title":"Expert Opin Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"bbaa061","DOI":"10.1093\/bib\/bbaa061","volume":"22","author":"Wang C.C.","year":"2021","unstructured":"Wang C.C.; Zhao Y.; Chen X.; Drug-pathway association prediction: From experimental results to computational models. Brief Bioinform 2021,22(3),bbaa061","journal-title":"Brief Bioinform"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.bmc.2019.05.007","volume":"27","author":"Nan X.","year":"2019","unstructured":"Nan X.; Jiang Y.F.; Li H.J.; Wang J.H.; Wu Y.C.; Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors. Bioorg Med Chem 2019,27(13),2801-2812","journal-title":"Bioorg Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"19361","DOI":"10.3390\/molecules201019361","volume":"20","author":"Wu C.","year":"2015","unstructured":"Wu C.; Wang M.; Tang Q.; Luo R.; Chen L.; Zheng P.; Zhu W.; Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit. Molecules 2015,20(10),19361-19371","journal-title":"Molecules"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1900113","DOI":"10.1002\/ardp.201900113","volume":"352","author":"El-Helby A.G.A.","year":"2019","unstructured":"El-Helby A.G.A.; Sakr H.; Eissa I.H.; Abulkhair H.; Al-Karmalawy A.A.; El-Adl K.; Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR\u20102 inhibitors. Arch Pharm (Weinheim) 2019,352(10),1900113","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"103422","DOI":"10.1016\/j.bioorg.2019.103422","volume":"94","author":"Mahdy H.A.","year":"2020","unstructured":"Mahdy H.A.; Ibrahim M.K.; Metwaly A.M.; Belal A.; Mehany A.B.M.; El-Gamal K.M.A.; El-Sharkawy A.; Elhendawy M.A.; Radwan M.M.; Elsohly M.A.; Eissa I.H.; Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2020,94,103422","journal-title":"Bioorg Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.bmcl.2005.04.056","volume":"15","author":"Garaj V.","year":"2005","unstructured":"Garaj V.; Puccetti L.; Fasolis G.; Winum J.Y.; Montero J.L.; Scozzafava A.; Vullo D.; Innocenti A.; Supuran C.T.; Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005,15(12),3102-3108","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1021\/acs.jmedchem.8b00770","volume":"61","author":"Bozdag M.","year":"2018","unstructured":"Bozdag M.; Carta F.; Ceruso M.; Ferraroni M.; McDonald P.C.; Dedhar S.; Supuran C.T.; Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem 2018,61(14),6328-6338","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1515\/tjb-2020-0238","volume":"46","year":"2021","unstructured":"Yurtta\u015f L.; Akalin \u00c7ift\u00e7i, G.; Temel, H.E. Evaluation of new sulfathiazole derivatives as antiproliferative agents. Turk Biyokim Derg 2021,46(5),533-539","journal-title":"Turk Biyokim Derg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/14756366.2017.1334650","volume":"32","author":"Ghorab M.M.","year":"2017","unstructured":"Ghorab M.M.; Alsaid M.S.; Soliman A.M.; Ragab F.A.; VEGFR-2 inhibitors and apoptosis inducers: Synthesis and molecular design of new benzo [g] quinazolin bearing benzenesulfonamide moiety. J Enzyme Inhib Med Chem 2017,32(1),893-907","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1016\/j.bmc.2006.06.020","volume":"14","author":"Rostom S.A.F.","year":"2006","unstructured":"Rostom S.A.F.; Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg Med Chem 2006,14(19),6475-6485","journal-title":"Bioorg Med Chem"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4172\/2161-0444.1000272","volume":"05","author":"Abdelaziz A.M.","year":"2015","unstructured":"Abdelaziz A.M.; Synthesis and evaluation of 5-Chloro-2-Methoxy-N-(4-Sulphamoylphenyl) benzamide derivatives as anti-cancer Agents. Med Chem 2015,05(06),253-260","journal-title":"Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"104842","DOI":"10.1016\/j.bioorg.2021.104842","volume":"111","author":"Ahmed M.F.","year":"2021","unstructured":"Ahmed M.F.; Santali E.Y.; Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2021,111,104842","journal-title":"Bioorg Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ejmech.2010.03.030","volume":"45","author":"Al-Said M.S.","year":"2010","unstructured":"Al-Said M.S.; Ghorab M.M.; Al-qasoumi S.I.; El-Hossary E.M.; Noaman E.; Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides. Eur J Med Chem 2010,45(7),3011-3018","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ejmech.2015.09.001","volume":"103","author":"Pingaew R.","year":"2015","unstructured":"Pingaew R.; Prachayasittikul V.; Worachartcheewan A.; Nantasenamat C.; Prachayasittikul S.; Ruchirawat S.; Prachayasittikul V.; Novel 1,4-naphthoquinone-based sulfonamides: Synthesis, QSAR, anticancer and antimalarial studies. Eur J Med Chem 2015,103,446-459","journal-title":"Eur J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11030-011-9324-3","volume":"15","author":"Ou L.","year":"2011","unstructured":"Ou L.; Han S.; Ding W.; Jia P.; Yang B.; Medina-Franco J.L.; Giulianotti M.A.; Chen J.Z.; Yu Y.; Parallel synthesis of novel antitumor agents: 1,2,3-triazoles bearing biologically active sulfonamide moiety and their 3D-QSAR. Mol Divers 2011,15(4),927-946","journal-title":"Mol Divers"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1016\/j.bmcl.2015.08.026","volume":"25","author":"Yan X.Q.","year":"2015","unstructured":"Yan X.Q.; Wang Z.C.; Li Z.; Wang P.F.; Qiu H.Y.; Chen L.W.; Lu X.Y.; Lv P.C.; Zhu H.L.; Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2\/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis. Bioorg Med Chem Lett 2015,25(20),4664-4671","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/ajhp\/57.9.834b","volume":"57","author":"Miller J.L.","year":"2000","unstructured":"Miller J.L.; Troglitazone withdrawn from market. Am J Health Syst Pharm 2000,57(9),834","journal-title":"Am J Health Syst Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-009-0700-y","volume":"124","author":"Colin C.","year":"2010","unstructured":"Colin C.; Salamone S.; Grillier-Vuissoz I.; Boisbrun M.; Kuntz S.; Lecomte J.; Chapleur Y.; Flament S.; New troglitazone derivatives devoid of PPAR\u03b3 agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res Treat 2010,124(1),101-110","journal-title":"Breast Cancer Res Treat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"111939","DOI":"10.1016\/j.ejmech.2019.111939","volume":"187","author":"Dupommier D.","year":"2020","unstructured":"Dupommier D.; Muller C.; Comoy C.; Mazerbourg S.; Bordessa A.; Piquard E.; Pawlak M.; Piquard F.; Martin H.; De Fays E.; Grandemange S.; Flament S.; Boisbrun M.; New desulfured troglitazone derivatives: Improved synthesis and biological evaluation. Eur J Med Chem 2020,187,111939","journal-title":"Eur J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejmech.2014.06.015","volume":"83","author":"Bordessa A.","year":"2014","unstructured":"Bordessa A.; Colin-Cassin C.; Grillier-Vuissoz I.; Kuntz S.; Mazerbourg S.; Husson G.; Vo M.; Flament S.; Martin H.; Chapleur Y.; Boisbrun M.; Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds. Eur J Med Chem 2014,83,129-140","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejmech.2012.02.044","volume":"51","author":"Salamone S.","year":"2012","unstructured":"Salamone S.; Colin C.; Grillier-Vuissoz I.; Kuntz S.; Mazerbourg S.; Flament S.; Martin H.; Richert L.; Chapleur Y.; Boisbrun M.; Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. Eur J Med Chem 2012,51,206-215","journal-title":"Eur J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1016\/j.bmcl.2004.08.017","volume":"14","author":"Chen H.","year":"2004","unstructured":"Chen H.; Fan Y.H.; Natarajan A.; Guo Y.; Iyasere J.; Harbinski F.; Luus L.; Christ W.; Aktas H.; Halperin J.A.; Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett 2004,14(21),5401-5405","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.molstruc.2017.10.077","volume":"1154","author":"Asati V.","year":"2018","unstructured":"Asati V.; Bharti S.K.; Design, synthesis and molecular modeling studies of novel thiazolidine-2,4-dione derivatives as potential anti-cancer agents. J Mol Struct 2018,1154,406-417","journal-title":"J Mol Struct"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1016\/j.bmcl.2012.05.098","volume":"22","author":"Dakin L.A.","year":"2012","unstructured":"Dakin L.A.; Block M.H.; Chen H.; Code E.; Dowling J.E.; Feng X.; Ferguson A.D.; Green I.; Hird A.W.; Howard T.; Keeton E.K.; Lamb M.L.; Lyne P.D.; Pollard H.; Read J.; Wu A.J.; Zhang T.; Zheng X.; Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 2012,22(14),4599-4604","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejmech.2013.02.030","volume":"63","author":"Romagnoli R.","year":"2013","unstructured":"Romagnoli R.; Baraldi P.G.; Salvador M.K.; Camacho M.E.; Balzarini J.; Bermejo J.; Est\u00e9vez F.; Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione. Eur J Med Chem 2013,63,544-557","journal-title":"Eur J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bioorg.2016.06.006","volume":"67","author":"Bhanushali U.","year":"2016","unstructured":"Bhanushali U.; Rajendran S.; Sarma K.; Kulkarni P.; Chatti K.; Chatterjee S.; Ramaa C.S.; 5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2. Bioorg Chem 2016,67,139-147","journal-title":"Bioorg Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejmech.2012.10.044","volume":"59","author":"Azizmohammadi M.","year":"2013","unstructured":"Azizmohammadi M.; Khoobi M.; Ramazani A.; Emami S.; Zarrin A.; Firuzi O.; Miri R.; Shafiee A.; 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 2013,59,15-22","journal-title":"Eur J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2013.05.044","volume":"66","author":"Havrylyuk D.","year":"2013","unstructured":"Havrylyuk D.; Zimenkovsky B.; Vasylenko O.; Day C.W.; Smee D.F.; Grellier P.; Lesyk R.; Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. Eur J Med Chem 2013,66,228-237","journal-title":"Eur J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejmech.2013.03.011","volume":"63","author":"Suthar S.K.","year":"2013","unstructured":"Suthar S.K.; Jaiswal V.; Lohan S.; Bansal S.; Chaudhary A.; Tiwari A.; Alex A.T.; Joesph A.; Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. Eur J Med Chem 2013,63,589-602","journal-title":"Eur J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1016\/j.bmcl.2009.09.057","volume":"19","author":"Li Q.","year":"2009","unstructured":"Li Q.; Al-Ayoubi A.; Guo T.; Zheng H.; Sarkar A.; Nguyen T.; Eblen S.T.; Grant S.; Kellogg G.E.; Zhang S.; Structure\u2013activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1\/2 inhibitors. Bioorg Med Chem Lett 2009,19(21),6042-6046","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s00044-011-9623-3","volume":"21","author":"Mohan R.","year":"2012","unstructured":"Mohan R.; Sharma A.K.; Gupta S.; Ramaa C.S.; Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med Chem Res 2012,21(7),1156-1165","journal-title":"Med Chem Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejmech.2013.10.078","volume":"71","author":"Nagarapu L.","year":"2014","unstructured":"Nagarapu L.; Yadagiri B.; Bantu R.; Kumar C.G.; Pombala S.; Nanubolu J.; Studies on the synthetic and structural aspects of benzosuberones bearing 2, 4-thiazolidenone moiety as potential anti-cancer agents. Eur J Med Chem 2014,71,91-97","journal-title":"Eur J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"103522","DOI":"10.1016\/j.bioorg.2019.103522","volume":"95","author":"Tilekar K.","year":"2020","unstructured":"Tilekar K.; Upadhyay N.; J\u00e4nsch N.; Schweipert M.; Mrowka P.; Meyer-Almes F.J.; Ramaa C.S.; Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. Bioorg Chem 2020,95,103522","journal-title":"Bioorg Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"103934","DOI":"10.1016\/j.bioorg.2020.103934","volume":"100","author":"Upadhyay N.","year":"2020","unstructured":"Upadhyay N.; Tilekar K.; J\u00e4nsch N.; Schweipert M.; Hess J.D.; Henze Macias L.; Mrowka P.; Aguilera R.J.; Choe J.; Meyer-Almes F.J.; Ramaa C.S.; Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: In silico studies, synthesis, and biological evaluation. Bioorg Chem 2020,100,103934","journal-title":"Bioorg Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1016\/j.bmcl.2007.05.059","volume":"17","author":"Li W.","year":"2007","unstructured":"Li W.; Lu Y.; Wang Z.; Dalton J.T.; Miller D.D.; Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett 2007,17(15),4113-4117","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/10426507.2016.1239197","volume":"192","author":"Mahmoodi N.O.","year":"2017","unstructured":"Mahmoodi N.O.; Mohammadi Zeydi M.; Biazar E.; Kazeminejad Z.; Synthesis of novel thiazolidine-4-one derivatives and their anticancer activity. Phosphorus Sulfur Silicon Relat Elem 2017,192(3),344-350","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2000279","DOI":"10.1002\/ardp.202000279","volume":"354","author":"El-Adl K.","year":"2021","unstructured":"El-Adl K.; El-Helby A.G.A.; Sakr H.; Ayyad R.R.; Mahdy H.A.; Nasser M.; Abulkhair H.S.; El-Hddad S.S.A.; Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5\u2010[(4\u2010chloro\/2,4\u2010dichloro)benzylidene]thiazolidine\u20102,4\u2010dione derivatives as VEGFR\u20102 inhibitors. Arch Pharm (Weinheim) 2021,354(2),2000279","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2000079","DOI":"10.1002\/ardp.202000079","volume":"353","author":"El-Adl K.","year":"2020","unstructured":"El-Adl K.; Sakr H.; Nasser M.; Alswah M.; Shoman F.M.A.; 5\u2010(4\u2010Methoxybenzylidene)thiazolidine\u20102,4\u2010dione\u2010derived VEGFR\u20102 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Arch Pharm (Weinheim) 2020,353(9),2000079","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"104059","DOI":"10.1016\/j.bioorg.2020.104059","volume":"102","author":"El-Adl K.","year":"2020","unstructured":"El-Adl K.; El-Helby A.A.; Sakr H.; Eissa I.H.; El-Hddad S.S.A.; Shoman M.I.A.; F.; Design, F. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. Bioorg Chem 2020,102,104059","journal-title":"Bioorg Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1080\/10406638.2020.1836004","volume":"42","author":"Francis T.","year":"2022","unstructured":"Francis T.; Dixit S.R.; Kumar B.R.P.; Discovery of rhodanine and thiazolidinediones as novel scaffolds for EGFR inhibition: Design, synthesis, analysis and CoMSIA studies. Polycycl Aromat Compd 2022,42(5),2483-2499","journal-title":"Polycycl Aromat Compd"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fendo.2018.00372","volume":"9","author":"Andrzejewski S.","year":"2018","unstructured":"Andrzejewski S.; Siegel P.M.; St-Pierre J.; metabolic profiles associated with metformin efficacy in cancer. Front Endocrinol (Lausanne) 2018,9,372","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1900075","DOI":"10.1002\/ardp.201900075","volume":"352","author":"Zhou S.","year":"2019","unstructured":"Zhou S.; Xu L.; Cao M.; Wang Z.; Xiao D.; Xu S.; Deng J.; Hu X.; He C.; Tao T.; Wang W.; Guan A.; Yang X.; Anticancer properties of novel pyrazole\u2010containing biguanide derivatives with activating the adenosine monophosphate\u2010activated protein kinase signaling pathway. Arch Pharm (Weinheim) 2019,352(9),1900075","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=51","first-page":"701","volume":"8","author":"Narise K.","year":"2014","unstructured":"Narise K.; Okuda K.; Enomoto Y.; Hirayama T.; Nagasawa H.; Optimization of biguanide derivatives as selective antitumor agents blocking adaptive stress responses in the tumor microenvironment. Drug Des Devel Ther 2014,8,701-717","journal-title":"Drug Des Devel Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/cancers13143588","volume":"13","author":"Ng L.","year":"2021","unstructured":"Ng L.; Foo D.C.C.; Wong C.K.H.; Man A.T.K.; Lo O.S.H.; Law W.L.; Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single center study. Cancers (Basel) 2021,13(14),3588","journal-title":"Cancers (Basel)"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"FC14","DOI":"10.1111\/crj.12098","volume":"9","author":"Amritha C.A.","year":"2015","unstructured":"Amritha C.A.; Kumaravelu P.; Chellathai D.D.; Evaluation of anti cancer effects of DPP-4 inhibitors in colon cancer- An In vitro Study. J Clin Diagn Res 2015,9(12),FC14-FC16","journal-title":"J Clin Diagn Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"19515","DOI":"10.1039\/D0NJ03774E","volume":"44","author":"Emami L.","year":"2020","unstructured":"Emami L.; Faghih Z.; Sakhteman A.; Rezaei Z.; Faghih Z.; Salehi F.; Khabnadideh S.; Design, synthesis, molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents. New J Chem 2020,44(45),19515-19531","journal-title":"New J Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00044-014-1143-5","volume":"24","author":"Facchinetti V.","year":"2015","unstructured":"Facchinetti V.; Moreth M.; Gomes C.R.B.; do \u00d3 Pessoa C.; Rodrigues F.A.R.; Cavalcanti B.C.; Oliveira A.C.A.; Carneiro T.R.; Gama I.L.; de Souza M.V.N.; Evaluation of (2S,3R)-2-(amino)-[4-(N-benzylarenesulfonamido)-3-hydroxy-1-phenylbutane derivatives: A promising class of anticancer agents. Med Chem Res 2015,24(2),533-542","journal-title":"Med Chem Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"9492","DOI":"10.1021\/jm300667v","volume":"55","author":"Zeng L.F.","year":"2012","unstructured":"Zeng L.F.; Wang Y.; Kazemi R.; Xu S.; Xu Z.L.; Sanchez T.W.; Yang L.M.; Debnath B.; Odde S.; Xie H.; Zheng Y.T.; Ding J.; Neamati N.; Long Y.Q.; Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem 2012,55(22),9492-9509","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1039\/C2OB26710A","volume":"11","author":"Wang Y.","year":"2013","unstructured":"Wang Y.; Xu Z.L.; Ai J.; Peng X.; Lin J.P.; Ji Y.C.; Geng M.Y.; Long Y.Q.; Investigation on the 1,6-naphthyridine motif: Discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors. Org Biomol Chem 2013,11(9),1545-1562","journal-title":"Org Biomol Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1021\/jm0500931","volume":"48","author":"Thompson A.M.","year":"2005","unstructured":"Thompson A.M.; Delaney A.M.; Hamby J.M.; Schroeder M.C.; Spoon T.A.; Crean S.M.; Showalter H.D.H.; Denny W.A.; Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J Med Chem 2005,48(14),4628-4653","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1021\/jm000161d","volume":"43","author":"Thompson A.M.","year":"2000","unstructured":"Thompson A.M.; Connolly C.J.C.; Hamby J.M.; Boushelle S.; Hartl B.G.; Amar A.M.; Kraker A.J.; Driscoll D.L.; Steinkampf R.W.; Patmore S.J.; Vincent P.W.; Roberts B.J.; Elliott W.L.; Klohs W.; Leopold W.R.; Showalter H.D.H.; Denny W.A.; 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase. J Med Chem 2000,43(22),4200-4211","journal-title":"J Med Chem"},{"key":"ref=60","first-page":"01","volume":"10","author":"Modi S. J.","year":"2020","unstructured":"Modi S. J.; Modh D. H.; Kulkarni V. M.; sights into the structural features of anticancer 1,6-naphthyridines and pyridopyrimidines as VEGFR-2 inhibitors: 3D-QSAR stud J Appl Pharm Sci, 2020,10(10),01-22","journal-title":"J Appl Pharm Sci,"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2022.2053206","volume":"15","author":"Modh D.H.","year":"2022","unstructured":"Modh D.H.; Modi S.J.; Deokar H.; Yadav S.; Kulkarni V.M.; Fibroblast growth factor receptor (FGFR) inhibitors as anticancer agents: 3D-QSAR, molecular docking and dynamics simulation studies of 1, 6-naphthyridines and pyridopyrimidines. J Biomol Struct Dyn 2022,15,1-16","journal-title":"J Biomol Struct Dyn"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/jm3013097","volume":"56","author":"La Regina G.","year":"2013","unstructured":"La Regina G.; Bai R.; Rensen W.M.; Di Cesare E.; Coluccia A.; Piscitelli F.; Famiglini V.; Reggio A.; Nalli M.; Pelliccia S.; Da Pozzo E.; Costa B.; Granata I.; Porta A.; Maresca B.; Soriani A.; Iannitto M.L.; Santoni A.; Li J.; Miranda Cona M.; Chen F.; Ni Y.; Brancale A.; Dondio G.; Vultaggio S.; Varasi M.; Mercurio C.; Martini C.; Hamel E.; Lavia P.; Novellino E.; Silvestri R.; Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem 2013,56(1),123-149","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.22146\/ijp.730","volume":"32","author":"Hmood K.S.","year":"2021","unstructured":"Hmood K.S.; Kubba A.A.R.M.; Al-bayati R.I.; Saleh A.M.; Am Synthesis, docking study and in vitro anticancer evaluation of some new flurbiprofen derivatives against MCF-7 and WRL-68 Cell Lines. Indones J Pharm 2021,32(1),17-34","journal-title":"Indones J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.12991\/201317389","volume":"17","author":"Aydin S.","year":"2013","unstructured":"Aydin S.; Kaushik-Basu N.; Arora P.; Basu A.; Nichols D.B.; Talele T.T.; Akkurt M.; \u00c7elik I.; B\u00fcy\u00fckgung\u00f6r O.; GunizKucukguzel, \u015e. Microwave Assisted synthesis of some novel flurbiprofen hydrazidehydrazones as Anti-HCV NS5B and Anticancer Agents. Marmara Pharm J 2013,17(1),26-34","journal-title":"Marmara Pharm J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14756366.2018.1474878","volume":"33","author":"El-Azab A.S.","year":"2018","unstructured":"El-Azab A.S.; Abdel-Aziz A.A.M.; Abou-Zeid L.A.; El-Husseiny W.M.; El Morsy A.M.; El-Gendy M.A.; El-Sayed M.A.A.; Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies. J Enzyme Inhib Med Chem 2018,33(1),989-998","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"23680","DOI":"10.1039\/C6RA28525B","volume":"7","author":"Kummari B.","year":"2017","unstructured":"Kummari B.; Polkam N.; Ramesh P.; Anantaraju H.; Yogeeswari P.; Anireddy J.S.; Guggilapu S.D.; Babu B.N.; Design and synthesis of 1,2,3-triazole\u2013etodolac hybrids as potent anticancer molecules. RSC Advances 2017,7(38),23680-23686","journal-title":"RSC Advances"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"75s","DOI":"10.1177\/096032718400300109","volume":"3","author":"Prescott L.F.","year":"1984","unstructured":"Prescott L.F.; Clinical features and management of analgesic poisoning. Hum Toxicol 1984,3((1_suppl)(Suppl.),),75s-84S","journal-title":"Hum Toxicol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2727619","volume":"2018","author":"Althagafi I.","year":"2018","unstructured":"Althagafi I.; El-Metwaly N.M.; Elghalban M.G.; Farghaly T.A.; Khedr A.M.; Synthesis of pyrazolone derivatives and their nanometer Ag(I) complexes and physicochemical, DNA binding, antitumor, and theoretical implementations. Bioinorg Chem Appl 2018,2018,1-15","journal-title":"Bioinorg Chem Appl"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bioorg.2017.04.001","volume":"72","author":"Gu W.","year":"2017","unstructured":"Gu W.; Dai Y.; Qiang H.; Shi W.; Liao C.; Zhao F.; Huang W.; Qian H.; Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met\/VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg Chem 2017,72,116-122","journal-title":"Bioorg Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/jm201331s","volume":"55","author":"Liu L.","year":"2012","unstructured":"Liu L.; Norman M.H.; Lee M.; Xi N.; Siegmund A.; Boezio A.A.; Booker S.; Choquette D.; D\u2019Angelo N.D.; Germain J.; Yang K.; Yang Y.; Zhang Y.; Bellon S.F.; Whittington D.A.; Harmange J.C.; Dominguez C.; Kim T.S.; Dussault I.; Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series. J Med Chem 2012,55(5),1868-1897","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"103916","DOI":"10.1016\/j.bioorg.2020.103916","volume":"101","author":"Dawood D.H.","year":"2020","unstructured":"Dawood D.H.; Nossier E.S.; Ali M.M.; Mahmoud A.E.; Synthesis and molecular docking study of new pyrazole derivatives as potent anti-breast cancer agents targeting VEGFR-2 kinase. Bioorg Chem 2020,101,103916","journal-title":"Bioorg Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1021\/jm201330u","volume":"55","author":"Norman M.H.","year":"2012","unstructured":"Norman M.H.; Liu L.; Lee M.; Xi N.; Fellows I.; D\u2019Angelo N.D.; Dominguez C.; Rex K.; Bellon S.F.; Kim T.S.; Dussault I.; Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J Med Chem 2012,55(5),1858-1867","journal-title":"J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1016\/j.bmcl.2011.10.055","volume":"21","author":"Tripathy R.","year":"2011","unstructured":"Tripathy R.; McHugh R.J.; Ghose A.K.; Ott G.R.; Angeles T.S.; Albom M.S.; Huang Z.; Aimone L.D.; Cheng M.; Dorsey B.D.; Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of selectivity by a benzyloxy group. Bioorg Med Chem Lett 2011,21(24),7261-7264","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00044-013-0636-y","volume":"23","author":"Shamsuzzaman S.","year":"2014","unstructured":"Shamsuzzaman S.; Mashrai A.; Ahmad A.; Dar A.M.; Khanam H.; Danishuddin M.; Khan A.U.; Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer and antimicrobial agents. Med Chem Res 2014,23(1),348-362","journal-title":"Med Chem Res"},{"key":"ref=75","first-page":"26","volume":"11","author":"Adhikari S.","year":"2021","unstructured":"Adhikari S.; Singh M.; Sharma P.; Arora S.; Pyrazolones as a Potential Anticancer Scaffold: Recent Trends and Future Perspectives. J Appl Pharm Sci 2021,11,26-37","journal-title":"J Appl Pharm Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"103752","DOI":"10.1016\/j.bioorg.2020.103752","volume":"98","author":"Fadaly W.A.A.","year":"2020","unstructured":"Fadaly W.A.A.; Elshaier Y.A.M.M.; Hassanein E.H.M.; Abdellatif K.R.A.; New 1,2,4-triazole\/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies. Bioorg Chem 2020,98,103752","journal-title":"Bioorg Chem"},{"key":"ref=77","first-page":"2659","volume":"30","author":"Bocca C.","year":"2010","unstructured":"Bocca C.; Bozzo F.; Bassignana A.; Miglietta A.; Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide. Anticancer Res 2010,30(7),2659-2666","journal-title":"Anticancer Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.phrs.2015.12.025","volume":"104","author":"Qiu H.Y.","year":"2016","unstructured":"Qiu H.Y.; Wang P.F.; Li Z.; Ma J.T.; Wang X.M.; Yang Y.H.; Zhu H.L.; Synthesis of dihydropyrazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition. Pharmacol Res 2016,104,86-96","journal-title":"Pharmacol Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/13543784.17.2.197","volume":"17","author":"Sch\u00f6nthal A.H.","year":"2008","unstructured":"Sch\u00f6nthal A.H.; Chen T.C.; Hofman F.M.; Louie S.G.; Petasis N.A.; Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008,17(2),197-208","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2174\/1573406418666220309123648","volume":"18","author":"Kassab A.E.","year":"2022","unstructured":"Kassab A.E.; El-Nassan H.B.; Abdelhaleem E.F.; Khalil O.M.; Design and synthesis of novel celecoxib analogues with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Med Chem 2022,18(8),903-914","journal-title":"Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"102966","DOI":"10.1016\/j.bioorg.2019.102966","volume":"88","author":"Catarro M.","year":"2019","unstructured":"Catarro M.; Serrano J.L.; Ramos S.S.; Silvestre S.; Almeida P.; Nimesulide analogues: From anti-inflammatory to antitumor agents. Bioorg Chem 2019,88,102966","journal-title":"Bioorg Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ejmech.2011.11.012","volume":"47","author":"Zhong B.","year":"2012","unstructured":"Zhong B.; Cai X.; Chennamaneni S.; Yi X.; Liu L.; Pink J.J.; Dowlati A.; Xu Y.; Zhou A.; Su B.; From COX-2 inhibitor nimesulide to potent anti-cancer agent: Synthesis, in vitro, in vivo and pharmacokinetic evaluation. Eur J Med Chem 2012,47(1),432-444","journal-title":"Eur J Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jsbmb.2011.03.018","volume":"126","author":"Zhong B.","year":"2011","unstructured":"Zhong B.; Cai X.; Yi X.; Zhou A.; Chen S.; Su B.; In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells. J Steroid Biochem Mol Biol 2011,126(1-2),10-18","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bmcl.2016.12.030","volume":"27","author":"Mareddy J.","year":"2017","unstructured":"Mareddy J.; Suresh N.; Kumar C.G.; Kapavarapu R.; Jayasree A.; Pal S.; 1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents. Bioorg Med Chem Lett 2017,27(3),518-523","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jsps.2022.03.004","volume":"30","author":"Jaragh-Alhadad L.A.","year":"2022","unstructured":"Jaragh-Alhadad L.A.; Ali M.S.; Methoxybenzamide derivative of nimesulide from anti-fever to anti-cancer: Chemical characterization and cytotoxicity. Saudi Pharm J 2022,30(5),485-493","journal-title":"Saudi Pharm J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1016\/j.bmcl.2009.09.109","volume":"19","author":"Su B.","year":"2009","unstructured":"Su B.; Chen S.; Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Bioorg Med Chem Lett 2009,19(23),6733-6735","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"129455","DOI":"10.1016\/j.molstruc.2020.129455","volume":"1228","author":"Harras M.F.","year":"2021","unstructured":"Harras M.F.; Sabour R.; Ammar Y.A.; Mehany A.B.M.; Farrag A.M.; Eissa S.I.; Design synthesis and cytotoxicity studies of some novel indomethacin-based heterocycles as anticancer and apoptosis inducing agents. J Mol Struct 2021,1228,129455","journal-title":"J Mol Struct"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejmech.2016.02.036","volume":"113","author":"Sever B.","year":"2016","unstructured":"Sever B.; Alt\u0131ntop, M.D.; Ku\u015f G.; \u00d6zkurt, M.; \u00d6zdemir, A.; Kaplanc\u0131kl\u0131 Z.A. Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies. Eur J Med Chem 2016,113,179-186","journal-title":"Eur J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.semcancer.2020.01.010","volume":"68","author":"Adasme M.F.","year":"2021","unstructured":"Adasme M.F.; Parisi D.; Sveshnikova A.; Schroeder M.; Structure-based drug repositioning: Potential and limits. Semin Cancer Biol 2021,68,192-198","journal-title":"Semin Cancer Biol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"Talevi A.","year":"2020","unstructured":"Talevi A.; Bellera C.L.; Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 2020,15(4),397-401","journal-title":"Expert Opin Drug Discov"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","volume":"68","author":"Issa N.T.","year":"2021","unstructured":"Issa N.T.; Stathias V.; Sch\u00fcrer S.; Dakshanamurthy S.; Machine and deep learning approaches for cancer drug repurposing. Semin Cancer Biol 2021,68,132-142","journal-title":"Semin Cancer Biol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666230509123036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216707\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666230509123036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T09:48:41Z","timestamp":1703756921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216707\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557523666230509123036","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}